Trial · NCT07893717
Motivational Interviewing Intervention for Families With Overweight and Obesity
NCT07893717, Not applicable, Active not recruiting, Universidad Autonoma de Baja California
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Motivational Interviewing Intervention for Families With Overweight and Obesity. Trials, record NCT07893717. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893717
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Motivational Interviewing Intervention for Families With Overweight and Obesity
- NCT number
- NCT07893717
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Universidad Autonoma de Baja California
- Conditions
- Obesity & Overweight
- Interventions
- Motivational interviewing to reduce obesity, Traditional nutritional counseling
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body composition | At the beginning, at the midpoint of the intervention (at 5 months), and at the end-that is, at 10 months. | Participants' body weight will be assessed via direct measurement and expressed in kilograms. Body mass index will be calculated from body weight and height and expressed in kg/m². Waist circumference will be measured and expressed in centimeters. Body fat percentage will be determined using the InBody 270 and expressed as a percentage. Muscle mass percentage will be determined using the InBody 270 and expressed as a percentage. |
| Secondary | Depression | At the beginning, at 5 months (the midpoint), and at the end-that is, at 10 months-when the intervention concludes. | Depression symptoms will be assessed using the Beck Depression Inventory-II (BDI-II). The result will be expressed as the total score obtained on the questionnaire, where a higher score indicates a greater presence of depressive symptoms. |
| Secondary | State anxiety | At the beginning, at 5 months (the midpoint), and at the end-that is, at 10 months-when the intervention concludes. | State anxiety will be assessed using the State-Trait Anxiety Inventory (STAI), specifically the state anxiety scale. The result will be expressed as the total score obtained on the scale, with a higher score indicating a higher level of state anxiety. |
| Secondary | Quality life | At the beginning, at 5 months (the midpoint), and at the end-that is, at 10 months-when the intervention concludes. | Quality of life will be assessed using the WHOQOL-BREF (World Health Organization Quality of Life-BREF), which consists of 26 questions. Results will be expressed in terms of the scores obtained across the instrument's dimensions and the overall quality of life score. |
| Secondary | Sleep quality | At the beginning, at 5 months (the midpoint), and at the end-that is, at 10 months-when the intervention concludes. | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The result will be expressed as the global score obtained on the questionnaire, where a higher score indicates poorer sleep quality. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893717
GET https://conductscience.org/api/trials/v1/NCT07893717/registered